QUEBEC, Feb. 9 /CNW Telbec/ - Victhom Human Bionics Inc. ("Victhom" or
the "Company", TSX-V: VHB) - At the request of Market Surveillance, the
Company wishes to comment on the recent and unusual trading activity in
its common shares. The Company is not aware of any specific
information not currently disclosed which might explain the recent
trading activity and increase in the market price of its shares.
However, the Company would like to inform its investors that its
partner, Ossur, during its investors conference call held yesterday
concurrent with the release of its 2010 annual financial statements,
reconfirmed the information previously announced by the Company that
the Power Knee Second Generation would become commercially available in
In addition and as previously announced by Victhom in its Q-3 press
release, Neurostream Technologies, General Partnership has not yet
achieved a milestone as per the partnership agreement, a situation that
is dependent on a number of factors that are not entirely under the
Company's control. The Company's partner has continued to fund
Neurostream's operations on a voluntary basis.
Victhom discovers, develops and manufactures bionic devices involved in
the treatment of a variety of physical and physiological dysfunctions.
Victhom Biotronix business developed the Power Knee, the world's first
and only motor-powered, artificially intelligent prosthesis for
above-knee amputees. The Power Knee is commercialized by Ossur, a
global leader in the orthotics and prosthetics ("O&P") market. Victhom
also has a 44.4% interest in Neurostream Technologies, General
Partnership, a joint venture with Otto Bock HealthCare, whose objective
is to bring to market the Neurostep® System, and to develop neuromodulation products in other indications
such as sleep apnea.
Some of the statements made herein may constitute forward-looking
statements. These statements relate to future events or our future
financial performance and involve known and unknown risks,
uncertainties and other factors that may cause Victhom's actual
results, performance or achievements to be materially different from
those expressed or implied by any of Victhom's statements. Actual
events or results may differ materially. We disclaim any intention, and
assume no obligation, to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE VICTHOM HUMAN BIONICS INC.
For further information: